Practical geriatric assessment for older adults with early-stage non-small cell lung cancer receiving SBRT
Official title: Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Run by Brigham and Women's Hospital · NCT06987890 · Data updated 2026-11-12
This project will test whether a brief Practical Geriatric Assessment (PGA) can be used with adults 65+ who have stage I–II non-small cell lung cancer and are receiving stereotactic body radiation therapy to identify care needs and guide supportive referrals.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | May 26, 2025 |
| Main results expected | December 26, 2026 |
| Study ends | December 26, 2026 |
| Registry record updated | August 25, 2026 |
| Trial ID | NCT06987890 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 65 and older with radiographically or pathologically confirmed stage I–II NSCLC who are planning to receive SBRT and can complete questionnaires in English or with an interpreter.
✕Probably not a fit
Patients who already receive a full geriatrician-led comprehensive geriatric assessment or those unable to engage with questionnaires may derive little additional benefit from the PGA.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional project at Brigham and Women's Hospital implements the PGA—a 10–15-minute, provider-administered geriatric screening tool—for patients aged 65 and older with stage I–II NSCLC who are scheduled for SBRT. Participants complete the PGA prior to treatment so clinicians can identify issues in function, nutrition, cognition, social support, and comorbidity and refer patients to services such as nutrition counseling, physical therapy, or social work as indicated. Because comprehensive geriatric assessments are resource-intensive and underused, the study examines the feasibility and acceptability of embedding the abbreviated PGA into routine pre-SBRT care. There are no exclusion criteria beyond age and diagnosis, and the project gathers information on uptake, time burden, and patient acceptability of the PGA.
Why it matters
Potential benefit: If successful, the PGA could help clinicians quickly identify older patients' needs and connect them to appropriate supportive services without requiring geriatric specialists.
How similar studies have gone: Comprehensive geriatric assessment has demonstrated benefits in older adults with cancer, and abridged tools like the PGA are recommended by ASCO, SIOG, and CARG, but real-world implementation and patient acceptability of the PGA remain less well proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 65 years old at time of study enrollment. * Radiographically or pathologically confirmed stage I-II non-small cell lung cancer. * All patients must have undergone appropriate complete imaging of their cancer consistent with the standard of care. * Patient is expected to undergo stereotactic body radiation therapy (SBRT) * Able to read questions in English or willing to complete survey questionnaires with the assistance of an interpreter. Exclusion Criteria: * There are no exclusion criteria.
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.